title: Effect of alvimopan on return of bowel function after robot-assisted radical cystectomy.
abstract: BACKGROUND
  Alvimopan has been shown to improve time to return of bowel function in patients undergoing bowel resection. The objective of this study is to determine if alvimopan has similar benefits for patients undergoing robot-assisted radical cystectomy (RARC).
  
  
  METHODS
  All RARC cases were reviewed from January 2008 to March 2012. All patients during this time were administered alvimopan unless they had been receiving narcotics preoperatively. Patients receiving alvimopan received a preoperative dose of 12 mg perorally and then were dosed twice daily for 7 days or until first bowel movement. Clinicopathologic outcomes were summarized and compared, and functional outcomes of treated patients were compared with outcomes of untreated patients.
  
  
  RESULTS
  One hundred seventeen RARCs meeting study criteria were performed. All urinary diversions used an extracorporeal approach. Urinary diversions consisted of 50 Studer neobladders, 22 Indiana pouches, and 45 ileal conduits. Fifty-four patients received alvimopan, and 63 did not. The median time to first bowel movement was 5 days in the alvimopan group and 6 days in the untreated group (P=.03). Median time to solid diet was 6 days in the treated group and 7 days in the untreated group (P=.03). There was a trend toward fewer hospital days in the alvimopan group (alvimopan, 8 days; untreated, 9 days; P=.1).
  
  
  CONCLUSIONS
  Alvimopan administration appears to reduce the time to return of bowel function and initiation of diet following RARC. This was a trend toward shorter hospitalization in the alvimopan group. Alvimopan should be considered in ongoing research into protocols to aid in shorter convalescence following RARC.
authors.affiliation: City of Hope National Medical Center , Duarte, California.
authors.forename: Scott
authors.initials: S
authors.lastname: Tobis
authors.forename: Jonathan E
authors.initials: JE
authors.lastname: Heinlen
authors.forename: Nora
authors.initials: N
authors.lastname: Ruel
authors.forename: Clayton
authors.initials: C
authors.lastname: Lau
authors.forename: Mark
authors.initials: M
authors.lastname: Kawachi
authors.forename: Timothy
authors.initials: T
authors.lastname: Wilson
authors.forename: Kevin
authors.initials: K
authors.lastname: Chan
mesh_terms: D015653:Cystectomy / Q000379:methods*; D013505:Digestive System Surgical Procedures; D005260:Female; D005765:Gastrointestinal Agents / Q000627:therapeutic use*; D006801:Humans; D007422:Intestines / Q000187:drug effects / Q000502:physiology; D007902:Length of Stay; D008297:Male; D008875:Middle Aged; D010880:Piperidines / Q000627:therapeutic use*; D020127:Recovery of Function / Q000187:drug effects* / Q000502:physiology; D065287:Robotic Surgical Procedures / Q000379:methods*; D001749:Urinary Bladder Neoplasms / Q000601:surgery; D014547:Urinary Diversion / Q000379:methods*
chemical_list: D005765:Gastrointestinal Agents; D010880:Piperidines; C419502:alvimopan